

Learn what could put travelers at increased risk

A closer look at the types of travelers you may meet in your practice



Actor portrayal

The Occasional Traveler

Lily is going on her dream vacation—visiting Kenya!

She's excited to take it all in:

- Relaxing by the coast
- Seeing wildlife on a safari

Learn what could put Lily at risk +



Actor portrayal

The Business Traveler

Ben is heading to Brazil for a big meeting.

He'll spend most of his time in a conference room, but he also might be:

- Sightseeing after hours
- Experiencing local culture outside the city

See why Ben's trip could be risky +



Actor portrayal

The Student Abroad

Mateo is prepping for 6 months of studying in Thailand.

He can't wait to learn beyond the classroom:

- Hiking to historical locations
- Visiting neighboring countries

Learn about Mateo's risk factors +

INDICATION

IXCHIQ is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.

This indication is approved under accelerated approval based on anti-CHIKV neutralizing antibody levels. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies.

SELECTED SAFETY INFORMATION


Contraindications

Do not administer IXCHIQ to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised), or to individuals with a history of a severe allergic reaction to any component of the vaccine.



The Occasional Traveler

Lily only travels once in a while, so she's very excited about her vacation. However, she may not be aware of the risks of mosquito-borne chikungunya



Lily is going on her dream vacation to Kenya

She is visiting her family's home country and planning to check items off her bucket list! During her visit, she wants to do a little bit of everything—relax by the coast, try local cuisine, and see the big 5 animals of African safari.

Lily's Risk Factors

- Kenya has had chikungunya outbreaks in the past¹
- Lily is planning to go on a safari, meaning she'll spend a lot of time outdoors and around wildlife
- Lily mentions she likes to watch the sunset when she's on vacation, which could increase her risk since disease-carrying mosquitoes may be more active at dusk²

During Your Consult

Lily is worried that she'll get this vaccine and still contract CHIKV. She's wondering if she should even bother getting vaccinated.

! Now is a great time to talk to Lily about the strong and robust seroresponse rates seen in IXCHIQ® (chikungunya vaccine, live) clinical trials.^{3,4}

CHIKV=chikungunya virus.

SELECTED SAFETY INFORMATION (cont'd)

Warnings and Precautions

Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of IXCHIQ.

Vaccination with IXCHIQ may cause severe or prolonged chikungunya-like adverse reactions. Severe chikungunya-like adverse reactions that prevented daily activity and/or required medical intervention occurred in 1.6% of 3,082 IXCHIQ recipients and no placebo recipients. Fourteen IXCHIQ recipients had prolonged (duration at least 30 days) chikungunya-like adverse reactions.

Potential for vertical transmission of vaccine virus and fetal/neonatal adverse reactions. Vertical transmission of wild-type CHIKV from pregnant individuals with viremia at delivery is common and can cause potentially fatal CHIKV disease in neonates. It is not known if the vaccine virus can be vertically transmitted and cause fetal or neonatal adverse reactions. Decisions to administer IXCHIQ during pregnancy should take into consideration the individual's risk of exposure to wild-type CHIKV, gestational age, and risks to the fetus or neonate from vertical transmission of wild-type CHIKV.



IVE)

The Business Traveler

Ben is an experienced business traveler and thinks he knows all of the risks



Actor portrayal

Ben is heading to Brazil for a big meeting

He is visiting for a large supply chain meeting and is just planning to go from his hotel room to the boardroom. If given the chance, he would like to enjoy some authentic experiences—either with local colleagues or on his own.

Ben's Risk Factors

- Brazil has had chikungunya outbreaks in the past⁵
- Ben might add unplanned activities to his trip, which could increase his time spent outdoors or bring him to rural areas

During Your Consult

Ben says he has had travel consults before and has never heard of chikungunya or been recommended a vaccine for it.

! This is a great time to mention that IXCHIQ® (chikungunya vaccine, live) is the first vaccine approved to protect against chikungunya for adults who are at increased risk of exposure to CHIKV.³

CHIKV=chikungunya virus.

SELECTED SAFETY INFORMATION (cont'd)

Warnings and Precautions (cont'd)

Syncope can occur with administration of IXCHIQ. Procedures should be in place to avoid injury from fainting.

IXCHIQ may not protect all individuals who receive the vaccine.

Adverse Reactions

In clinical studies, the most common injection site reaction (>10%) was tenderness (11%). The most common systemic adverse reactions (>10%) were headache (32%), fatigue (29%), myalgia (24%), arthralgia (17%), fever (14%), and nausea (11%).



IVE)

The Student Abroad

Mateo will be traveling for an extended trip to study abroad. He should also learn his risks for mosquito-borne diseases



Actor portrayal

Mateo is prepping for a semester in Thailand

He is excited to spend 6 months studying and exploring in Thailand. Mateo enjoys hiking and visiting historical locations, so this is a perfect place for him to learn! He's also hoping to visit neighboring countries during his free weekends.

Mateo's Risk Factors

- Thailand and some neighboring countries have had chikungunya outbreaks in the past⁶⁻⁸
- Mateo will be in Thailand for an extended period of time, which increases the likelihood that he will come in contact with mosquitoes
- Because Mateo enjoys going on hikes, he could spend a lot of time outdoors

During Your Consult

Mateo is worried about side effects. He says he is busy and doesn't want to be laid up with side effects after getting the vaccine.

- ! **Talking to Mateo about the established safety profile of IXCHIQ® (chikungunya vaccine, live) could help ease his concerns.**³

SELECTED SAFETY INFORMATION (cont'd)

Use in Specific Populations

Pregnancy

There is a pregnancy registry to monitor outcomes in women exposed to IXCHIQ during pregnancy and it may be reached by contacting OXON Epidemiology at 1-855-417-6214. There are no adequate and well-controlled studies of IXCHIQ in pregnant individuals, and human data available from clinical trials with IXCHIQ are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy.

To report **SUSPECTED ADVERSE REACTIONS**, contact Valneva at 1-844-349-4276 or VAERS at 1-800-822-7967 or <http://vaers.hhs.gov>.

Please see full [Prescribing Information](#) for IXCHIQ.

References:

1. Chikungunya – Kenya. World Health Organization. Published May 28, 2016. Accessed May 3, 2024. <https://www.afro.who.int/news/chikungunya-kenya>
2. Dengue and the *aedes aegypti* mosquito. Hawaii State Department of Health. Accessed May 10, 2024. https://health.hawaii.gov/docd/files/2015/11/CDC_aegypti_factsheet.pdf
3. IXCHIQ. Prescribing information. Valneva USA Inc.; 2023.
4. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2023;401(10394):2138-2147.
5. Amaral JK, Taylor PC, Schoen RT. Brazil at the center of chikungunya outbreaks. *J Glob Infect Dis*. 2023;15(3):131-132.
6. Khongwicht S, Chansaenroj J, Thongmee T, et al. Large-scale outbreak of chikungunya virus infection in Thailand, 2018–2019. *PLoS One*. 2021;16(3):e0247314.
7. Rachmat A, Kelly GC, Hontz RD, et al. Clinical and epidemiologic evaluation of a 2020 chikungunya outbreak in Cambodia. *BMC Infect Dis*. 2022;22(1):949.
8. Kyaw AK, Tun MMN, Nabeshima T, et al. Chikungunya virus infection in blood donors and patients during outbreak, Mandalay, Myanmar, 2019. *Emerging Infect Dis*. 2020;26(11):2741-2745.